HRP20010632B1 - Matrix tablet enabling prolonged release of gliclazide after administration by the oral route - Google Patents

Matrix tablet enabling prolonged release of gliclazide after administration by the oral route

Info

Publication number
HRP20010632B1
HRP20010632B1 HR20010632A HRP20010632A HRP20010632B1 HR P20010632 B1 HRP20010632 B1 HR P20010632B1 HR 20010632 A HR20010632 A HR 20010632A HR P20010632 A HRP20010632 A HR P20010632A HR P20010632 B1 HRP20010632 B1 HR P20010632B1
Authority
HR
Croatia
Prior art keywords
gliclazide
administration
matrix tablet
oral route
prolonged release
Prior art date
Application number
HR20010632A
Other languages
English (en)
Croatian (hr)
Inventor
Huet De Barochez Bruno
Wuthrich Patrick
Martin Louis
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9541429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010632(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HRP20010632A2 publication Critical patent/HRP20010632A2/xx
Publication of HRP20010632B1 publication Critical patent/HRP20010632B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20010632A 1999-02-01 2001-08-30 Matrix tablet enabling prolonged release of gliclazide after administration by the oral route HRP20010632B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9901082A FR2788981B1 (fr) 1999-02-01 1999-02-01 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale
PCT/FR1999/002520 WO2000018373A1 (fr) 1999-02-01 1999-10-15 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale

Publications (2)

Publication Number Publication Date
HRP20010632A2 HRP20010632A2 (en) 2005-02-28
HRP20010632B1 true HRP20010632B1 (en) 2006-02-28

Family

ID=9541429

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010632A HRP20010632B1 (en) 1999-02-01 2001-08-30 Matrix tablet enabling prolonged release of gliclazide after administration by the oral route

Country Status (37)

Country Link
US (1) US6733782B1 (hu)
EP (1) EP1148871B1 (hu)
JP (2) JP4716465B2 (hu)
KR (1) KR100491600B1 (hu)
CN (1) CN1160061C (hu)
AP (1) AP1243A (hu)
AT (1) ATE296621T1 (hu)
AU (1) AU764516B2 (hu)
BR (1) BR9917012A (hu)
CA (1) CA2273420C (hu)
CZ (1) CZ298196B6 (hu)
DE (1) DE69925639T2 (hu)
DK (1) DK1148871T3 (hu)
EA (1) EA002625B1 (hu)
EE (1) EE05024B1 (hu)
ES (1) ES2241323T3 (hu)
FR (1) FR2788981B1 (hu)
GE (1) GEP20053501B (hu)
HK (1) HK1043049A1 (hu)
HR (1) HRP20010632B1 (hu)
HU (1) HU225693B1 (hu)
ID (1) ID30225A (hu)
IL (2) IL144246A0 (hu)
ME (1) ME00436B (hu)
NO (1) NO329951B1 (hu)
NZ (1) NZ512878A (hu)
OA (1) OA11756A (hu)
PL (1) PL194505B1 (hu)
PT (1) PT1148871E (hu)
RS (1) RS50121B (hu)
SA (1) SA00210446B1 (hu)
SK (1) SK285209B6 (hu)
TR (1) TR200102002T2 (hu)
UA (1) UA68414C2 (hu)
WO (1) WO2000018373A1 (hu)
YU (1) YU53101A (hu)
ZA (1) ZA200106305B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
SE0200539D0 (sv) * 2002-02-25 2002-02-25 Metcon Medicin Ab Granulation process and starch granulate
CN100391459C (zh) * 2003-05-26 2008-06-04 沈阳药科大学 甲磺酸多沙唑嗪缓释制剂
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
WO2005105109A1 (fr) * 2004-04-29 2005-11-10 Lotus Pharmaceutical Co., Ltd. Pastilles a liberation orale modifiee et leur procede de preparation
CN100413491C (zh) * 2004-06-14 2008-08-27 北京德众万全药物技术开发有限公司 一种难溶性药物的控释制剂
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
EP1946780B1 (en) * 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
TR200704897A1 (tr) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
TR200708938A2 (tr) * 2007-12-26 2008-11-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salım sağlayan gliklazid tablet
ITFI20080016A1 (it) * 2008-02-05 2009-08-06 Valpharma Sa Formulazioni farmaceutiche orali contenenti gliclazide.
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2009140279A2 (en) * 2008-05-12 2009-11-19 Concert Pharmaceuticals, Inc. Sulfonyl urea compounds
EP2181705A1 (en) 2008-10-31 2010-05-05 Disphar International B.V. Sustained-release formulation of gliclazide
WO2010102071A1 (en) * 2009-03-03 2010-09-10 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
JP5669837B2 (ja) 2010-06-16 2015-02-18 帝人ファーマ株式会社 放出制御型の有核錠剤
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20150031737A1 (en) 2012-02-24 2015-01-29 Ranbaxy Laboratories Limited Stabilized controlled-release pharmaceutical composition comprising gliclazide
EP2958548A1 (en) 2013-02-19 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A production process for gliclazide formulations
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
HUE043951T2 (hu) 2014-07-18 2019-09-30 Sanofi Sa Eljárás rákgyanús beteg aflibercepttel történõ kezelése kimenetének elõrejelzésére
WO2016042568A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of gliclazide
CN111329841B (zh) * 2020-03-04 2021-11-19 山东鲁抗医药集团赛特有限责任公司 格列齐特缓释片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US4056623A (en) * 1975-03-05 1977-11-01 Science Union Et Cie, Societe Francaise De Recherche Medicale Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
DE4336159A1 (de) * 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Hochwirksame, den Wirkstoff schnell oder kontrolliert freisetzende Zubereitungsformen von Sulfonylharnstoffen und Verfahren zu deren Herstellung
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.

Also Published As

Publication number Publication date
IL144246A (en) 2006-12-10
CZ298196B6 (cs) 2007-07-18
HUP0105365A2 (hu) 2002-04-29
CN1342068A (zh) 2002-03-27
BR9917012A (pt) 2002-04-16
DE69925639D1 (de) 2005-07-07
EP1148871B1 (fr) 2005-06-01
DK1148871T3 (da) 2005-09-19
IL144246A0 (en) 2002-05-23
EE05024B1 (et) 2008-06-16
HU225693B1 (en) 2007-06-28
AP2001002212A0 (en) 2001-09-30
ES2241323T3 (es) 2005-10-16
PL194505B1 (pl) 2007-06-29
NZ512878A (en) 2002-05-31
ZA200106305B (en) 2002-07-31
NO20013757D0 (no) 2001-07-31
YU53101A (sh) 2004-05-12
CZ20012661A3 (cs) 2001-11-14
NO329951B1 (no) 2011-01-31
WO2000018373A1 (fr) 2000-04-06
CA2273420A1 (fr) 2000-08-01
PT1148871E (pt) 2005-08-31
HK1043049A1 (en) 2002-09-06
JP2008179649A (ja) 2008-08-07
PL356707A1 (en) 2004-06-28
JP4716465B2 (ja) 2011-07-06
TR200102002T2 (tr) 2002-01-21
HUP0105365A3 (en) 2002-11-28
UA68414C2 (en) 2004-08-16
RS50121B (sr) 2009-03-25
SK10952001A3 (sk) 2001-12-03
CA2273420C (fr) 2002-07-09
HRP20010632A2 (en) 2005-02-28
ATE296621T1 (de) 2005-06-15
KR100491600B1 (ko) 2005-05-27
EP1148871A1 (fr) 2001-10-31
AU764516B2 (en) 2003-08-21
EA200100827A1 (ru) 2002-02-28
US6733782B1 (en) 2004-05-11
CN1160061C (zh) 2004-08-04
EE200100398A (et) 2002-10-15
JP2002525310A (ja) 2002-08-13
ID30225A (id) 2001-11-15
AP1243A (en) 2004-02-02
GEP20053501B (en) 2005-05-10
NO20013757L (no) 2001-08-09
FR2788981A1 (fr) 2000-08-04
DE69925639T2 (de) 2006-04-27
EA002625B1 (ru) 2002-06-27
SK285209B6 (sk) 2006-08-03
OA11756A (en) 2005-07-19
KR20010093307A (ko) 2001-10-27
ME00436B (me) 2011-10-10
SA00210446B1 (ar) 2006-10-11
AU6098299A (en) 2000-04-17
FR2788981B1 (fr) 2002-05-17

Similar Documents

Publication Publication Date Title
HRP20010632B1 (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route
MY136318A (en) Sustained-release tablet composition
MXPA03007712A (es) Sales farmaceuticas.
NZ508808A (en) 4-benzyl piperidine alkylsulfoxide heterocycles and their use as subtype-selective NMDA receptor antagonists
DE60334678D1 (de) Antikörper enthaltende pharmazeutische lösungen
BR0015188A (pt) Composições farmacêuticas
IT1320586B1 (it) Struttura di supporto a braccio posteriore oscillante per motociclo.
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
MA26919A1 (fr) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3'] bipyridinyle sous une forme cristalline pure et procede de synthese.
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
ECSP066872A (es) Tabletas desintegrantes que comprenden licarbazepina
DK1171101T3 (da) Fremgangsmåde til fremstilling af en vanduoplöselig amorf depotmatrix
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
DK1523473T3 (da) Indolinderivater substitueret i position 6, deres fremstilling og anvendelse som lægemiddel.
BR0012553A (pt) Pastilhas contendo ambroxol
IT1318457B1 (it) Cartuccia per la perforazione dell'orecchio.
ATE284878T1 (de) Pharmazeutische verbindungen mit serotonin rezeptor aktivität
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
MA26823A1 (fr) Nouveaux derives de pyrimidine-2,4,6-trione, procede pour leur fabrication et agents pharmaceutiques contenant ces composes.
WO2002024146A3 (en) Methods of decreasing or preventing pain using spicamycin derivatives
IT1317841B1 (it) Derivati del 3,9-diazabiciclo(3.3.1)nonano ad attivita' analgesica.
PT1556380E (pt) Derivados de piridoindolona substituidos na posicao 3 por um grupo heterociclico, a sua preparacao e a sua aplicacao em terapeutica.
BRPI0408359A (pt) derivados de fenilpiridazina solúveis em água e medicamentos contendo os mesmos

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20180911

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20191015